Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 2467-2473

  Kang, Hye Seon ^a   Rhee, Chin Kook ^a   Kim, Sung Kyoung ^a   Kim, Jin Woo ^a   Lee, Sang Haak ^a   Yoon, Hyung Kyu ^a   Ahn, Joong Hyun ^a   Kim, Yong Hyun ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Chronic obstructive; Eosinophilia; Exacerbations; Intensive care unit; Neutrophilia; Pulmonary disease

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR;

AGED; ARTICLE; BLOOD CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE EXACERBATION; EMERGENCY WARD; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LEUKOCYTE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; OUTPATIENT DEPARTMENT; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DISEASE COURSE; IMMUNOLOGY; LUNG; MIDDLE AGED; MULTICENTER STUDY; NEUTROPHIL CHEMOTAXIS; ODDS RATIO; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; SOUTH KOREA; STATISTICAL MODEL; VERY ELDERLY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALS, UNIVERSITY; HUMANS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; NEUTROPHIL INFILTRATION; ODDS RATIO; PATIENT ADMISSION; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84989954170     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S116072     Document Type: Article

References (36)

1. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-120.
2. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc. 2004;1(2):109-114.
3. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662-671.
4. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906-913.
5. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48-55.
6. Gil H, Magy N, Mauny F, Dupond JL. [Value of eosinopenia in inflammatory disorders: an “old” marker revisited]. Rev Med Interne. 2003;24(7):431-435. French.
7. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67(11):970-976.
8. Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology. 2010;15(1):165-167.
9. Gao P, Zhang J, He X, Hao Y, Wang K, Gibson PG. Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2013;8(5):e57678.
10. Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation. 2013;36(5):1178-1185.
11. Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(suppl):S214-S219.
12. Eltboli O, Mistry V, Barker B, Brightling CE. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology. 2015;20(4):667-670.
13. Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2014;9:1101-1110.
14. Alaithan AM, Memon JI, Rehmani RS, Qureshi AA, Salam A. Chronic obstructive pulmonary disease: hospital and intensive care unit outcomes in the Kingdom of Saudi Arabia. Int J Chron Obstruct Pulmon Dis. 2012;7:819-823.
15. Khilnani GC, Banga A, Sharma SK. Predictors of mortality of patients with acute respiratory failure secondary to chronic obstructive pulmonary disease admitted to an intensive care unit: a one year study. BMC Pulm Med. 2004;4:12.
16. Garcia-Sanz MT, Pol-Balado C, Abellas C, Canive-Gomez JC, Anton-Sanmartin D, Gonzalez-Barcala FJ. Factors associated with hospital admission in patients reaching the emergency department with COPD exacerbation. Multidiscip Respir Med. 2012;7(1):6.
17. Chang C, Zhu H, Shen N, et al. Bacterial infection, airway and systemic inflammation and clinical outcomes before and after treatment of AECOPD, a longitudinal and cross-sectional study. COPD. 2015;12(1):19-30.
18. Weis N, Almdal T. C-reactive protein-can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med. 2006;17(2):88-91.
19. Crisafulli E, Torres A, Huerta A, et al. Predicting in-hospital treatment failure (#7 days) in patients with COPD exacerbation using antibiotics and systemic steroids. COPD. 2016;13(1):82-92.
20. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150(6 pt 1):1646-1652.
21. Zanini A, Cherubino F, Zampogna E, Croce S, Pignatti P, Spanevello A. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1155-1161.
22. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39-47.
23. Pizzichini MM, Popov TA, Efthimiadis A, et al. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med. 1996;154(4 pt 1):866-869.
24. Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest. 1995;108(1):10-15.
25. Hospers JJ, Schouten JP, Weiss ST, Rijcken B, Postma DS. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med. 1999;160(6):1869-1874.
26. Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB; Respiratory Effectiveness Group. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis. 2015;10:2439-2450.
27. Duman D, Aksoy E, Agca MC, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis. 2015;10:2469-2478.
28. Salturk C, Karakurt Z, Adiguzel N, et al. Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? Int J Chron Obstruct Pulmon Dis. 2015;10:1837-1846.
29. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354(9177):456-460.
30. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224-1238.
31. McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119(4):1190-1209.
32. Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2006;144(12):894-903.
33. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012;40(1):17-27.
34. Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalised exacerbations of COPD. Chest. Epub 2016 Feb 3.
35. Serafino-Agrusa L, Scichilone N, Spatafora M, Battaglia S. Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: a case-control study. Pulm Pharmacol Ther. 2016;37:89-94.
36. Altman LC, Hill JS, Hairfield WM, Mullarkey MF. Effects of corticosteroids on eosinophil chemotaxis and adherence. J Clin Invest. 1981;67(1):28-36.